ADXN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 May 2024 @ 12:02):

Stats
Today's Volume	7 834.00
Average Volume	19 986.00
Market Cap	12.33M
EPS	$0 ( 2024-04-04 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.105 (1.20%)

Volume Correlation

Long: -0.16 (neutral)

Short: -0.11 (neutral)

Signal:(65.892) Neutral

Addex Therapeutics Ltd Correlation

10 Most Positive Correlations
SVAC	0.974
CVGI	0.957
CYN	0.956
MESA	0.955
DARE	0.954
WISA	0.954
MCRB	0.952
UCTT	0.952
CFRX	0.952
CURI	0.952

10 Most Negative Correlations
NETE	-0.974
LDHA	-0.965
VLAT	-0.964
HORI	-0.964
LGAC	-0.96
MSDAU	-0.96
ABGI	-0.96
HCNE	-0.96
HERAU	-0.959
CRZN	-0.959

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Addex Therapeutics Ltd Correlation - Currency/Commodity

-0.37
( neutral )

-0.40
( neutral )

0.55
( weak )

-0.11
( neutral )

-0.73
( moderate negative )

0.18
( neutral )

Addex Therapeutics Ltd Financials

Annual	2023
Revenue:	$1.61M
Gross Profit:	$-5.32M (-329.99 %)
EPS:	$-0.140

FY	2023
Revenue:	$1.61M
Gross Profit:	$-5.32M (-329.99 %)
EPS:	$-0.140

FY	2022
Revenue:	$1.42M
Gross Profit:	$-13.20M (-928.06 %)
EPS:	$-0.460

FY	2021
Revenue:	$2.92M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.70

Financial Reports:

No articles found.

Addex Therapeutics Ltd

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.